Seres Therapeutics (MCRB) Stock: Falling Apart on Study Results

By |July 29th, 2016|

Seres Therapeutics Inc (NASDAQ: MCRB)

Seres Therapeutics had an incredibly rough day in the market today to cap the trading week off. Unfortunately, the company released top line results from a recent Phase 2 study. Unfortunately, the study did not meet its primary endpoint. Today, we’ll talk about what we saw from the study, how […]